Source: Healio News
Neurologic adverse events were generally manageable in patients with multiple myeloma after receiving ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy, according to CARTITUDE-2 data presented at the virtual ASCO Annual Meeting.
“Treatment-emerging neurotoxicities are known side effects of CAR-T cell therapies,” Hermann Einsele, MD, from the University Hospital of Würzburg in Germany, said in the presentation. “Here we present patient management strategies to identify and reduce the incidence of neurological adverse events in CARTITUDE-2.”
Researchers